Caris Life Sciences (CAI) EBIT (2024 - 2026)

Caris Life Sciences' EBIT history runs 3 years deep, the most recent figure standing at $5.3 million for Q1 2026.

• In Q1 2026, EBIT rose 109.11% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $108.3 million (up 148.62% YoY), while the FY2025 annual figure was $45.1 million, up 117.55% from the prior year.
• EBIT was $5.3 million for Q1 2026 at Caris Life Sciences, down from $88.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $88.4 million in Q4 2025 to a low of -$67.0 million in Q2 2024.
• Historically, EBIT has averaged -$14.3 million across 3 years, with a median of -$27.5 million in 2024.
• Biggest YoY gain for EBIT was 338.65% in 2025; the steepest drop was 73.16% in 2025.
• A 3-year view of EBIT shows it stood at -$37.0 million in 2024, then soared by 338.65% to $88.4 million in 2025, then sank by 94.03% to $5.3 million in 2026.
• The last three EBIT figures came in at $5.3 million (Q1 2026), $88.4 million (Q4 2025), and $32.6 million (Q3 2025), per Business Quant data.